Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
Tracking Information | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Received Date ICMJE | November 3, 2010 | ||||||||||||||||
Last Updated Date | January 31, 2012 | ||||||||||||||||
Start Date ICMJE | November 2010 | ||||||||||||||||
Primary Completion Date | August 2011 (final data collection date for primary outcome measure) | ||||||||||||||||
Current Primary Outcome Measures ICMJE |
Efficacy of Biphentin compared to placebo [ Time Frame: At end of Double-Blind Week 1 ] [ Designated as safety issue: No ] Efficacy of Biphentin compared to placebo, in the clinic setting, as measured by the Clinician ADHD-RS-IV in children and adolescents (aged 6 to 18) diagnosed with ADHD |
||||||||||||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||
Change History | Complete list of historical versions of study NCT01239030 on ClinicalTrials.gov Archive Site | ||||||||||||||||
Current Secondary Outcome Measures ICMJE |
Incidence of Adverse Events as a Measure of Safety and Tolerability [ Time Frame: During the 12-week study period ] [ Designated as safety issue: Yes ] Incidence of adverse findings using various measures of safety, tolerability, and quality of life assessments following administration of once daily Biphentin |
||||||||||||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||||
Current Other Outcome Measures ICMJE | |||||||||||||||||
Original Other Outcome Measures ICMJE | |||||||||||||||||
Descriptive Information | |||||||||||||||||
Brief Title ICMJE | Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD | ||||||||||||||||
Official Title ICMJE | A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD) | ||||||||||||||||
Brief Summary | This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER)capsules of three dose levels compared with a placebo group in pediatric patients with Attention Deficit Hyperactivity Disorder (ADHD) who are between 6 and 18 years old. |
||||||||||||||||
Detailed Description | This is a parallel, randomized, double-blind, multi-center, placebo-controlled, forced dose, phase 3 study to evaluate the safety and efficacy of Biphentin methylphenidate hydrochloride extended release capsules in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric and adolescent patients aged 6 up to 18 years. The study will have four phases: (1) Screening and washout; (2) Double-blind fixed dose study involving test drug at 10, 15, 20 or 40 mg/day or placebo for 1 week; (3) Open-label phase that includes dose optimization with doses starting at 10 mg, and allowed up to 60 mg; and (4) 30-day safety follow-up. Eight (8) visits may be required. The open-label period following the one double-blind fixed dose week provides additional opportunity for subjects to receive treatment with Biphentin. Extra unscheduled dose optimization visits are allowed as needed for additional dose titration visits during the open-label period. Various safety and tolerability, and quality of life assessments will be conducted. Biphentin is designed to be a single daily dose alternative to separate doses of immediate release methylphenidate by providing a biphasic plasma profile. It achieves a first Cmax more similar to immediate release methylphenidate. It also comes in eight (8), that allow better individualized dosing. |
||||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||||
Study Phase | Phase 3 | ||||||||||||||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
||||||||||||||||
Condition ICMJE |
|
||||||||||||||||
Intervention ICMJE | Drug: Biphentin Methylphenidate Extended Release Capsules
Biphentin Methylphenidate ER Once-A-Day Capsules
Other Name: Biphentin |
||||||||||||||||
Study Arm (s) |
|
||||||||||||||||
Publications * | |||||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||
Recruitment Information | |||||||||||||||||
Recruitment Status ICMJE | Completed | ||||||||||||||||
Enrollment ICMJE | 236 | ||||||||||||||||
Completion Date | November 2011 | ||||||||||||||||
Primary Completion Date | August 2011 (final data collection date for primary outcome measure) | ||||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||
Gender | Both | ||||||||||||||||
Ages | 6 Years to 18 Years | ||||||||||||||||
Accepts Healthy Volunteers | No | ||||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||||
Location Countries ICMJE | United States | ||||||||||||||||
Administrative Information | |||||||||||||||||
NCT Number ICMJE | NCT01239030 | ||||||||||||||||
Other Study ID Numbers ICMJE | RP-BP-EF002 | ||||||||||||||||
Has Data Monitoring Committee | No | ||||||||||||||||
Responsible Party | Rhodes Pharmaceuticals, L.P. | ||||||||||||||||
Study Sponsor ICMJE | Rhodes Pharmaceuticals, L.P. | ||||||||||||||||
Collaborators ICMJE | |||||||||||||||||
Investigators ICMJE |
|
||||||||||||||||
Information Provided By | Rhodes Pharmaceuticals, L.P. | ||||||||||||||||
Verification Date | January 2012 | ||||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |